寨卡疫苗效力评估:WHO/NIH会议报告
由于寨卡病毒病例自2016年初高峰后大幅下降,传统临床疾病终点效力试验难以实施。2018年3月WHO疫苗研究倡议与NIH/NIAID联合召开专家会议,探讨在疫情消退背景下证明寨卡候选疫苗效力的策略,并提出开发、监管等多方需考虑的要点,这些考量也可能适用于其他新兴感染疫苗的开发。
要点
- 寨卡发病率低使传统临床终点效力试验不可行。
- 需探索替代策略证明疫苗效力。
- 会议要点可能适用于其他新兴感染疫苗开发。
核心结论
- 在寨卡病毒传播低水平时期,需采用替代策略证明候选疫苗效力,以持续推进疫苗研发。
研究设计与样本
- WHO疫苗研究倡议与NIH/NIAID于2018年3月联合召开专家会议,形成会议报告。
主要发现
- 寨卡病例自2016年初高峰后下降至极低水平,使得3期现场效力试验可能不可行。
- 若干候选疫苗已快速推进至1期和2期临床试验。
- 缺乏持续病毒传播时,通过传统临床疾病终点效力研究评估疫苗效力可能困难。
- 寨卡仍在一些地区低水平传播,且当人群免疫消退后可能重新出现。
临床怎么用
- 为开发者和监管者等利益相关方提供在疫情消退时证明疫苗效力的考虑要点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since its peak in early 2016, the incidence of Zika virus (ZIKV) cases has declined to such low levels that Phase 3 field efficacy trials may be infeasible. While great progress was made to rapidly advance several vaccine candidates into Phase 1 and 2 clinical trials, in the absence of sustained viral transmission it may be difficult to evaluate the effectiveness of ZIKV vaccine candidates by conducting traditional clinical disease endpoint efficacy studies. However, ZIKV is still circulating at low levels in some areas and is likely to re-emerge in naïve populations or in sites of prior epidemics once population immunity wanes. Therefore, the public health need for a ZIKV vaccine remains. To facilitate continued ZIKV vaccine development efforts, the World Health Organization's Initiative for Vaccine Research and the National Institutes of Health's National Institute of Allergy and Infectious Diseases co-hosted a meeting of experts in March 2018 to identify strategies to demonstrate vaccine effectiveness in view of waning ZIKV disease incidence. This paper outlines points for consideration for developers, regulators, and other stakeholders working towards a licensed ZIKV vaccine. These deliberations may also be applicable to development of vaccines for other emerging infections where the size, unpredictability, and ephemeral nature of outbreaks makes clinical disease endpoint efficacy trials to demonstrate vaccine effectiveness infeasible.
引用
- Vannice KS, Cassetti MC, Eisinger RW, et al. Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine. 2019. PMID: 30639461. doi:10.1016/j.vaccine.2018.12.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。